Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese

Authors: Chunxiao Xu, Dan Zhou, Feixia Pan, Yi Liu, Dandan zhang, Aifen Lin, Xiaoping Miao, Yaqin Ni, Duo Lv, Shuai Zhang, Xiaobo Li, Yimin Zhu, Maode Lai

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Genes in inflammatory pathways play a pivotal role in the development of colorectal cancer. We conducted a two-stage case-control study and aimed at screening the colorectal cancer-associated genetic variations in inflammatory genes.

Methods

Twenty-three candidate variants were genotyped in 952 primary colorectal cancer cases and 875 cancer-free controls from eastern China. Promising single nucleotide polymorphisms were further genotyped in 518 cases and 554 controls from middle China. Expression quantitative trait loci and differential gene expression analyses were performed for the associated gene.

Results

rs2282151 presented consistently significant associations with the risk of colorectal cancer in both stages (odds ratio (95 % confidence interval) = 1.30 (1.16–1.46), risk allele = C, Pcombined = 8.9E-6). Gene expression quantitative trait loci analyzes uncovered consistent cis-regulatory signals which showed that the C allele of rs2282151 was associated with increased expression level of heat shock protein 90 alpha family class B member 1 (HSP90AB1). Then we found that the mRNA expression levels of HSP90AB1 were significantly higher in tumor tissues than normal tissues (fold-change = 1.83) in 28 pairs of colorectal tissue samples. The expression difference was consistent with data from online datasets. Additionally, we observed notable peaks of H3K27ac and H3K4me3 near the first intron of HSP90AB1 using ChIP-seq data from multiple cell lines (including HCT116).

Conclusions

Our findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
3.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM, Meunier C, Turbide C, Gros P, Beauchemin N. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32(3):367–78.CrossRefPubMed
4.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL) 6, IL8, tumor necrosis factor α, NFKB1, and peroxisome proliferator-activated receptor γ with colorectal cancer. Cancer Res. 2003;63(13):3560–6.PubMed
5.
Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed. 2006;5(1):15.CrossRefPubMedPubMedCentral
6.
Frank B, Hoffmeister M, Klopp N, Illig T, Chang‐Claude J, Brenner H. Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. Int J Cancer. 2010;127(12):2822–30.CrossRefPubMed
7.
Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29(7):2727–37.PubMed
8.
Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–17.CrossRefPubMed
9.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–9.CrossRefPubMed
10.
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66.CrossRefPubMed
11.
Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252–66.CrossRefPubMed
12.
Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14. e2105.CrossRefPubMed
13.
Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARγ. J Nutr. 2010;140(3):515–21.CrossRefPubMedPubMedCentral
14.
15.
Zhong C, Wang J, Li B, Xiang H, Ultsch M, Coons M, Wong T, Chiang NY, Clark S, Clark R. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res. 2013;19(16):4433–45.CrossRefPubMed
16.
17.
Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–82.CrossRefPubMed
18.
Tergaonkar V, Correa RG, Ikawa M, Verma IM. Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat Cell Biol. 2005;7(9):921–3.CrossRefPubMed
19.
Chung Y-C, Chaen Y-L, Hsu C-P. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006;26(5B):3905–11.PubMed
20.
21.
Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, Nexø BA, Raaschou-Nielsen O, Andersen PS, Overvad K. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res Fundam Mol Mech Mutagen. 2007;624(1):88–100.CrossRef
22.
Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, Hallmans G, Hemminki K, Lenner P, Försti A. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29(6):1202–6.CrossRefPubMed
23.
Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011;17(6):1452–62.CrossRefPubMedPubMedCentral
24.
Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006;15(6):1445–51.PubMed
25.
Rupertus K, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, Kollmar O. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis. 2014;31(4):447–59.CrossRefPubMed
26.
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin P-C. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009;69(20):7905–10.CrossRefPubMedPubMedCentral
27.
Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30.CrossRefPubMed
28.
Rubie C, Frick VO, Ghadjar P, Wagner M, Justinger C, Faust SK, Vicinus B, Gräber S, Kollmar O, Schilling MK. CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. J Transl Med. 2011;9(1):22–8.CrossRefPubMedPubMedCentral
29.
Wang H, Burnett T, Kono S, Haiman CA, Iwasaki M, Wilkens LR, Loo LWM, Berg DVD, Kolonel LN, Henderson BE. Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. Nat Commun. 2014;5:5.
30.
Zhang B, Jia WH, Matsuo K, Shin A, Xiang YB, Matsuda K, Sun HJ, Kim DH, Cheah PY, Ren Z. Genome-wide association study identifies a new SMAD7 risk variant associated with colorectal cancer risk in East Asians. Int J Cancer. 2014;135(4):948–55.CrossRefPubMedPubMedCentral
31.
Cui R, Okada Y, Jang SG, Ku JL, Park JG, Kamatani Y, Hosono N, Tsunoda T, Kumar V, Tanikawa C. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut. 2011;60(6):799–805.CrossRefPubMedPubMedCentral
32.
Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, Shin A, Sun HJ, Kim DH, Cai Q. Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nat Genet. 2014;46(6):533–42.CrossRefPubMedPubMedCentral
33.
Li Z, Yu D, Gan M, Shan Q, Yin X, Tang S, Zhang S, Shi Y, Zhu Y, Lai M. A genome-wide assessment of rare copy number variants in colorectal cancer. Oncotarget. 2015;6(28):26411–23.CrossRefPubMedPubMedCentral
34.
Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, Bell JT, Yang T-P, Meduri E, Barrett A. Mapping cis-and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012;44(10):1084–9.CrossRefPubMedPubMedCentral
35.
Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45(10):1238–43.CrossRefPubMedPubMedCentral
36.
Closa A, Cordero D, Sanzpamplona R, Solé X, Crousbou M, Parébrunet L, Berenguer A, Guino E, Lopezdoriga A, Guardiola J. Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis. Carcinogenesis. 2014;35(9):2039–46.CrossRefPubMedPubMedCentral
37.
Ongen H, Andersen CL, Bramsen JB, Oster B, Rasmussen MH, Ferreira PG, Sandoval J, Vidal E, Whiffin N, Planchon A. Putative cis-regulatory drivers in colorectal cancer. Nature. 2014;512(7512):87–90.PubMed
38.
Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816.CrossRefPubMed
39.
Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336–7.CrossRefPubMedPubMedCentral
40.
Zhou D, Li Z, Yu D, Wan L, Zhu Y, Lai M, Zhang D. Polymorphisms involving gain or loss of CpG sites are significantly enriched in trait-associated SNPs. Oncotarget. 2015;6:39995–40004.PubMedPubMedCentral
41.
Zhi D, Aslibekyan S, Irvin MR, Claas SA, Borecki IB, Ordovas JM, Absher DM, Arnett DK. SNPs located at CpG sites modulate genome-epigenome interaction. Epigenetics. 2013;8(8):802–6.CrossRefPubMedPubMedCentral
42.
Zhang S, Lu J, Zhao X, Wu W, Wang H, Lu J, Wu Q, Chen X, Fan W, Chen H. A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis. 2010;31(7):1251–8.CrossRefPubMed
43.
Haase M, Fitze G. HSP90AB1: Helping the good and the bad. Gene. 2015;575(2P1):171–86.PubMed
44.
Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761–72.CrossRefPubMed
45.
Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015;360(2):114–8.CrossRefPubMed
46.
Galigniana MD, Echeverría PC, Erlejman AG, Piwien-Pilipuk G. Role of molecular chaperones and TPR-domain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore. Nucleus. 2010;1(4):299–308.CrossRefPubMedPubMedCentral
47.
48.
Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene. 2004;23(31):5378–86.CrossRefPubMed
49.
Nagaraju GP, Long TE, Park W, Landry JC, Taliaferro-Smith LT, Farris AB, Diaz R, El-Rayes BF: Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. Mol Carcinog. 2014;54(10):1147-58.
50.
Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I. The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer. Anticancer Res. 2014;34(2):753–7.PubMed
51.
Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, Min Z. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 2012;31:70.CrossRefPubMedPubMedCentral
52.
Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Bufalo DD. Bcl-2 regulates HIF-1α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One. 2010;5(7):e11772.CrossRefPubMedPubMedCentral
Metadata
Title
A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese
Authors
Chunxiao Xu
Dan Zhou
Feixia Pan
Yi Liu
Dandan zhang
Aifen Lin
Xiaoping Miao
Yaqin Ni
Duo Lv
Shuai Zhang
Xiaobo Li
Yimin Zhu
Maode Lai
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2843-7

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case–control study

Research article

Microsatellite alteration and immunohistochemical expression profile of chromosome 9p21 in patients with sporadic renal cell carcinoma following surgical resection

Research article

Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample

Research article

High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma

Research article

Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases

Research article

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits